Long	O
-	O
term	O
outcomes	O
of	O
stereotactic	B:C3896609
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
with	O
fiducial	O
tracking	O
for	O
inoperable	O
stage	O
I	I:C0278504
non	I:C0278504
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	O
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
.	O

Long	O
-	O
term	O
outcomes	O
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	B:C3896609
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
with	O
fiducial	O
tracking	O
for	O
inoperable	O
stage	O
I	I:C0278504
non	I:C0278504
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	O
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
.	O

Long	O
-	O
term	O
outcomes	O
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
with	O
fiducial	B:C2826325
tracking	O
for	O
inoperable	O
stage	O
I	I:C0278504
non	I:C0278504
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	O
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
.	O

Long	O
-	O
term	O
outcomes	O
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
with	O
fiducial	O
tracking	B:C0546881
for	O
inoperable	O
stage	O
I	I:C0278504
non	I:C0278504
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	O
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
.	O

Long	O
-	O
term	O
outcomes	O
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
with	O
fiducial	O
tracking	O
for	O
inoperable	O
stage	B:C0278504
I	I:C0278504
non	I:C0278504
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	O
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
.	O

Long	O
-	O
term	O
outcomes	O
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
with	O
fiducial	O
tracking	O
for	O
inoperable	O
stage	O
I	I:C0278504
non	I:C0278504
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	B:C0278504
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
.	O

Stereotactic	B:C3896609
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
for	O
stage	O
I	I:C0278504
non	I:C0278504
-small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	O
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
is	O
considered	O
standard	O
of	I:C2936643
care	I:C2936643
in	O
the	O
medically	O
inoperable	O
patient	O
population	O
.	O

Stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	B:C3896609
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
for	O
stage	O
I	I:C0278504
non	I:C0278504
-small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	O
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
is	O
considered	O
standard	O
of	I:C2936643
care	I:C2936643
in	O
the	O
medically	O
inoperable	O
patient	O
population	O
.	O

Stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
for	O
stage	B:C0278504
I	I:C0278504
non	I:C0278504
-small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	O
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
is	O
considered	O
standard	O
of	I:C2936643
care	I:C2936643
in	O
the	O
medically	O
inoperable	O
patient	O
population	O
.	O

Stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
for	O
stage	O
I	I:C0278504
non	I:C0278504
-small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	B:C0278504
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
is	O
considered	O
standard	O
of	I:C2936643
care	I:C2936643
in	O
the	O
medically	O
inoperable	O
patient	O
population	O
.	O

Stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
for	O
stage	O
I	I:C0278504
non	I:C0278504
-small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	O
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
is	O
considered	O
standard	B:C2936643
of	I:C2936643
care	I:C2936643
in	O
the	O
medically	O
inoperable	O
patient	O
population	O
.	O

Stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
(	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
)	O
for	O
stage	O
I	I:C0278504
non	I:C0278504
-small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
(	O
non	O
-	I:C0278504
small	I:C0278504
cell	I:C0278504
lung	I:C0278504
cancer	I:C0278504
)	O
is	O
considered	O
standard	O
of	I:C2936643
care	I:C2936643
in	O
the	O
medically	O
inoperable	O
patient	O
population	B:C1257890
.	O

Multiple	B:C0087111
methods	I:C0087111
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
delivery	O
exist	O
including	O
fiducial	O
-	O
based	O
tumor	O
tracking	O
,	O
which	O
allows	O
for	O
smaller	O
treatment	O
margins	I:C0229985
and	O
avoidance	O
of	O
patient	O
immobilization	I:C0035260
devices	I:C0035260
.	O

Multiple	O
methods	I:C0087111
of	O
stereotactic	B:C3896609
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
delivery	O
exist	O
including	O
fiducial	O
-	O
based	O
tumor	O
tracking	O
,	O
which	O
allows	O
for	O
smaller	O
treatment	O
margins	I:C0229985
and	O
avoidance	O
of	O
patient	O
immobilization	I:C0035260
devices	I:C0035260
.	O

Multiple	O
methods	I:C0087111
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
delivery	B:C0011211
exist	O
including	O
fiducial	O
-	O
based	O
tumor	O
tracking	O
,	O
which	O
allows	O
for	O
smaller	O
treatment	O
margins	I:C0229985
and	O
avoidance	O
of	O
patient	O
immobilization	I:C0035260
devices	I:C0035260
.	O

Multiple	O
methods	I:C0087111
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
delivery	O
exist	O
including	O
fiducial	B:C2826325
-	O
based	O
tumor	O
tracking	O
,	O
which	O
allows	O
for	O
smaller	O
treatment	O
margins	I:C0229985
and	O
avoidance	O
of	O
patient	O
immobilization	I:C0035260
devices	I:C0035260
.	O

Multiple	O
methods	I:C0087111
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
delivery	O
exist	O
including	O
fiducial	O
-	O
based	O
tumor	B:C0027651
tracking	O
,	O
which	O
allows	O
for	O
smaller	O
treatment	O
margins	I:C0229985
and	O
avoidance	O
of	O
patient	O
immobilization	I:C0035260
devices	I:C0035260
.	O

Multiple	O
methods	I:C0087111
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
delivery	O
exist	O
including	O
fiducial	O
-	O
based	O
tumor	O
tracking	B:C0546881
,	O
which	O
allows	O
for	O
smaller	O
treatment	O
margins	I:C0229985
and	O
avoidance	O
of	O
patient	O
immobilization	I:C0035260
devices	I:C0035260
.	O

Multiple	O
methods	I:C0087111
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
delivery	O
exist	O
including	O
fiducial	O
-	O
based	O
tumor	O
tracking	O
,	O
which	O
allows	O
for	O
smaller	O
treatment	B:C0229985
margins	I:C0229985
and	O
avoidance	O
of	O
patient	O
immobilization	I:C0035260
devices	I:C0035260
.	O

Multiple	O
methods	I:C0087111
of	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
delivery	O
exist	O
including	O
fiducial	O
-	O
based	O
tumor	O
tracking	O
,	O
which	O
allows	O
for	O
smaller	O
treatment	O
margins	I:C0229985
and	O
avoidance	O
of	O
patient	B:C0035260
immobilization	I:C0035260
devices	I:C0035260
.	O

We	O
explore	O
the	O
long	O
-	O
term	O
clinical	B:C0243095
outcomes	I:C0243095
of	O
this	O
novel	O
fiducial	O
-	O
based	O
SBRT	O
method	I:C3896609
.	O

We	O
explore	O
the	O
long	O
-	O
term	O
clinical	O
outcomes	I:C0243095
of	O
this	O
novel	O
fiducial	B:C2826325
-	O
based	O
SBRT	O
method	I:C3896609
.	O

We	O
explore	O
the	O
long	O
-	O
term	O
clinical	O
outcomes	I:C0243095
of	O
this	O
novel	O
fiducial	O
-	O
based	O
SBRT	B:C3896609
method	I:C3896609
.	O

In	O
this	O
single	B:C1266869
institutional	I:C1266869
retrospective	O
review	O
,	O
we	O
detail	O
the	O
outcomes	O
of	O
medically	O
inoperable	O
pathologically	O
confirmed	O
stage	O
I	I:C0278504
NSCLC	I:C0278504
.	O

In	O
this	O
single	O
institutional	I:C1266869
retrospective	O
review	O
,	O
we	O
detail	O
the	O
outcomes	O
of	O
medically	O
inoperable	O
pathologically	O
confirmed	B:C0750484
stage	O
I	I:C0278504
NSCLC	I:C0278504
.	O

In	O
this	O
single	O
institutional	I:C1266869
retrospective	O
review	O
,	O
we	O
detail	O
the	O
outcomes	O
of	O
medically	O
inoperable	O
pathologically	O
confirmed	O
stage	B:C0278504
I	I:C0278504
NSCLC	I:C0278504
.	O

Patients	O
were	O
treated	B:C0332293
with	I:C0332293
the	O
Cyberknife	O
SBRT	O
system	I:C3896609
using	O
a	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
defined	O
as	O
a	O
5	O
-	O
mm	O
expansion	O
from	O
gross	O
tumor	O
volume	O
(	O
GTV	O
)	O
without	O
creation	O
of	O
an	O
internal	O
target	O
volume	O
(	O
ITV	O
)	O
.	O

Patients	O
were	O
treated	O
with	I:C0332293
the	O
Cyberknife	B:C1300683
SBRT	O
system	I:C3896609
using	O
a	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
defined	O
as	O
a	O
5	O
-	O
mm	O
expansion	O
from	O
gross	O
tumor	O
volume	O
(	O
GTV	O
)	O
without	O
creation	O
of	O
an	O
internal	O
target	O
volume	O
(	O
ITV	O
)	O
.	O

Patients	O
were	O
treated	O
with	I:C0332293
the	O
Cyberknife	O
SBRT	B:C3896609
system	I:C3896609
using	O
a	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
defined	O
as	O
a	O
5	O
-	O
mm	O
expansion	O
from	O
gross	O
tumor	O
volume	O
(	O
GTV	O
)	O
without	O
creation	O
of	O
an	O
internal	O
target	O
volume	O
(	O
ITV	O
)	O
.	O

Patients	O
were	O
treated	O
with	I:C0332293
the	O
Cyberknife	O
SBRT	O
system	I:C3896609
using	O
a	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
defined	O
as	O
a	O
5	O
-	O
mm	O
expansion	B:C0205229
from	O
gross	O
tumor	O
volume	O
(	O
GTV	O
)	O
without	O
creation	O
of	O
an	O
internal	O
target	O
volume	O
(	O
ITV	O
)	O
.	O

Pretreatment	O
and	O
posttreatment	O
pulmonary	B:C0024119
function	I:C0024119
test	I:C0024119
(	O
pulmonary	O
function	I:C0024119
test	I:C0024119
)	O
changes	O
and	O
evidence	O
of	O
late	O
radiological	O
rib	O
fractures	I:C0035522
were	O
analyzed	O
for	O
the	O
majority	O
of	O
patients	O
.	O

Pretreatment	O
and	O
posttreatment	O
pulmonary	O
function	I:C0024119
test	I:C0024119
(	O
pulmonary	B:C0024119
function	I:C0024119
test	I:C0024119
)	O
changes	O
and	O
evidence	O
of	O
late	O
radiological	O
rib	O
fractures	I:C0035522
were	O
analyzed	O
for	O
the	O
majority	O
of	O
patients	O
.	O

Pretreatment	O
and	O
posttreatment	O
pulmonary	O
function	I:C0024119
test	I:C0024119
(	O
pulmonary	O
function	I:C0024119
test	I:C0024119
)	O
changes	O
and	O
evidence	O
of	O
late	O
radiological	B:C0043299
rib	O
fractures	I:C0035522
were	O
analyzed	O
for	O
the	O
majority	O
of	O
patients	O
.	O

Pretreatment	O
and	O
posttreatment	O
pulmonary	O
function	I:C0024119
test	I:C0024119
(	O
pulmonary	O
function	I:C0024119
test	I:C0024119
)	O
changes	O
and	O
evidence	O
of	O
late	O
radiological	O
rib	B:C0035522
fractures	I:C0035522
were	O
analyzed	O
for	O
the	O
majority	O
of	O
patients	O
.	O

Sixty	O
-	O
one	O
patients	O
with	O
a	O
median	O
age	O
of	O
75	O
years	O
were	O
available	O
for	O
analysis	B:C0936012
.	O

The	O
majority	O
(	O
80	O
%	O
)	O
of	O
patients	O
were	O
deemed	O
to	O
be	O
medically	O
inoperable	O
due	O
to	O
underlying	O
pulmonary	B:C0024109
dysfunction	O
.	O

The	O
majority	O
(	O
80	O
%	O
)	O
of	O
patients	O
were	O
deemed	O
to	O
be	O
medically	O
inoperable	O
due	O
to	O
underlying	O
pulmonary	O
dysfunction	B:C0277785
.	O

Eleven	O
patients	O
(	O
18	O
%	O
)	O
developed	O
symptomatic	O
pneumothoraces	O
secondary	O
to	O
fiducial	B:C3888577
placement	I:C3888577
under	O
CT	O
guidance	I:C0475322
,	O
which	O
precipitously	O
dropped	I:C0243095
to	O
0	O
%	O
following	O
transition	O
to	O
bronchoscopic	O
fiducial	O
placement	I:C3888577
.	O

Eleven	O
patients	O
(	O
18	O
%	O
)	O
developed	O
symptomatic	O
pneumothoraces	O
secondary	O
to	O
fiducial	O
placement	I:C3888577
under	O
CT	B:C0475322
guidance	I:C0475322
,	O
which	O
precipitously	O
dropped	I:C0243095
to	O
0	O
%	O
following	O
transition	O
to	O
bronchoscopic	O
fiducial	O
placement	I:C3888577
.	O

Eleven	O
patients	O
(	O
18	O
%	O
)	O
developed	O
symptomatic	O
pneumothoraces	O
secondary	O
to	O
fiducial	O
placement	I:C3888577
under	O
CT	O
guidance	I:C0475322
,	O
which	O
precipitously	B:C0243095
dropped	I:C0243095
to	O
0	O
%	O
following	O
transition	O
to	O
bronchoscopic	O
fiducial	O
placement	I:C3888577
.	O

Eleven	O
patients	O
(	O
18	O
%	O
)	O
developed	O
symptomatic	O
pneumothoraces	O
secondary	O
to	O
fiducial	O
placement	I:C3888577
under	O
CT	O
guidance	I:C0475322
,	O
which	O
precipitously	O
dropped	I:C0243095
to	O
0	O
%	O
following	O
transition	O
to	O
bronchoscopic	B:C0179432
fiducial	O
placement	I:C3888577
.	O

Eleven	O
patients	O
(	O
18	O
%	O
)	O
developed	O
symptomatic	O
pneumothoraces	O
secondary	O
to	O
fiducial	O
placement	I:C3888577
under	O
CT	O
guidance	I:C0475322
,	O
which	O
precipitously	O
dropped	I:C0243095
to	O
0	O
%	O
following	O
transition	O
to	O
bronchoscopic	O
fiducial	B:C3888577
placement	I:C3888577
.	O

The	O
2	O
-	O
year	O
rib	B:C0035522
fracture	I:C0035522
risk	O
was	O
21.4	O
%	O
with	O
a	O
median	O
time	O
to	O
rib	O
fracture	I:C0035522
of	O
2.9	O
years	O
.	O

The	O
2	O
-	O
year	O
rib	O
fracture	I:C0035522
risk	B:C0582456
was	O
21.4	O
%	O
with	O
a	O
median	O
time	O
to	O
rib	O
fracture	I:C0035522
of	O
2.9	O
years	O
.	O

The	O
2	O
-	O
year	O
rib	O
fracture	I:C0035522
risk	O
was	O
21.4	O
%	O
with	O
a	O
median	O
time	O
to	O
rib	B:C0035522
fracture	I:C0035522
of	O
2.9	O
years	O
.	O

PFTs	B:C0024119
averaged	O
over	O
all	O
patients	O
and	O
parameters	O
demonstrated	O
small	O
absolute	O
declines	O
,	O
5.7	O
%	O
averaged	O
pulmonary	O
function	I:C0024119
test	I:C0024119
decline	O
,	O
at	O
approximately	O
1	O
year	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
but	O
only	O
the	O
diffusing	O
capacity	O
of	O
lung	O
for	O
carbon	O
monoxide	O
(	O
DLCO	O
)	O
demonstrated	O
a	O
statistically	O
significant	O
decline	O
(	O
10.29	O
vs.	O
9.01	O
mL/min/mmHg	O
,	O
p	O
=	O
0.01	O
)	O
.	O

PFTs	O
averaged	O
over	O
all	O
patients	O
and	O
parameters	O
demonstrated	O
small	O
absolute	O
declines	O
,	O
5.7	O
%	O
averaged	O
pulmonary	B:C0024119
function	I:C0024119
test	I:C0024119
decline	O
,	O
at	O
approximately	O
1	O
year	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
but	O
only	O
the	O
diffusing	O
capacity	O
of	O
lung	O
for	O
carbon	O
monoxide	O
(	O
DLCO	O
)	O
demonstrated	O
a	O
statistically	O
significant	O
decline	O
(	O
10.29	O
vs.	O
9.01	O
mL/min/mmHg	O
,	O
p	O
=	O
0.01	O
)	O
.	O

PFTs	O
averaged	O
over	O
all	O
patients	O
and	O
parameters	O
demonstrated	O
small	O
absolute	O
declines	O
,	O
5.7	O
%	O
averaged	O
pulmonary	O
function	I:C0024119
test	I:C0024119
decline	O
,	O
at	O
approximately	O
1	O
year	O
of	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
,	O
but	O
only	O
the	O
diffusing	O
capacity	O
of	O
lung	O
for	O
carbon	O
monoxide	O
(	O
DLCO	O
)	O
demonstrated	O
a	O
statistically	O
significant	O
decline	O
(	O
10.29	O
vs.	O
9.01	O
mL/min/mmHg	O
,	O
p	O
=	O
0.01	O
)	O
.	O

Despite	O
reduced	O
treatment	B:C0229985
margins	I:C0229985
and	O
lack	O
of	O
patient	O
immobilization	O
,	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
with	O
fiducial	O
-	O
based	O
tumor	O
tracking	O
achieves	O
clinically	O
comparable	O
long	O
-	O
term	O
outcomes	O
to	O
other	O
linac	O
-	O
based	O
SBRT	O
approaches	I:C3896609
.	O

Despite	O
reduced	O
treatment	O
margins	I:C0229985
and	O
lack	O
of	O
patient	O
immobilization	B:C0020944
,	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
with	O
fiducial	O
-	O
based	O
tumor	O
tracking	O
achieves	O
clinically	O
comparable	O
long	O
-	O
term	O
outcomes	O
to	O
other	O
linac	O
-	O
based	O
SBRT	O
approaches	I:C3896609
.	O

Despite	O
reduced	O
treatment	O
margins	I:C0229985
and	O
lack	O
of	O
patient	O
immobilization	O
,	O
stereotactic	B:C3896609
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
with	O
fiducial	O
-	O
based	O
tumor	O
tracking	O
achieves	O
clinically	O
comparable	O
long	O
-	O
term	O
outcomes	O
to	O
other	O
linac	O
-	O
based	O
SBRT	O
approaches	I:C3896609
.	O

Despite	O
reduced	O
treatment	O
margins	I:C0229985
and	O
lack	O
of	O
patient	O
immobilization	O
,	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
with	O
fiducial	B:C2826325
-	O
based	O
tumor	O
tracking	O
achieves	O
clinically	O
comparable	O
long	O
-	O
term	O
outcomes	O
to	O
other	O
linac	O
-	O
based	O
SBRT	O
approaches	I:C3896609
.	O

Despite	O
reduced	O
treatment	O
margins	I:C0229985
and	O
lack	O
of	O
patient	O
immobilization	O
,	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
with	O
fiducial	O
-	O
based	O
tumor	B:C0027651
tracking	O
achieves	O
clinically	O
comparable	O
long	O
-	O
term	O
outcomes	O
to	O
other	O
linac	O
-	O
based	O
SBRT	O
approaches	I:C3896609
.	O

Despite	O
reduced	O
treatment	O
margins	I:C0229985
and	O
lack	O
of	O
patient	O
immobilization	O
,	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
with	O
fiducial	O
-	O
based	O
tumor	O
tracking	B:C0546881
achieves	O
clinically	O
comparable	O
long	O
-	O
term	O
outcomes	O
to	O
other	O
linac	O
-	O
based	O
SBRT	O
approaches	I:C3896609
.	O

Despite	O
reduced	O
treatment	O
margins	I:C0229985
and	O
lack	O
of	O
patient	O
immobilization	O
,	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
with	O
fiducial	O
-	O
based	O
tumor	O
tracking	O
achieves	O
clinically	O
comparable	O
long	O
-	O
term	O
outcomes	O
to	O
other	O
linac	B:C0023730
-	O
based	O
SBRT	O
approaches	I:C3896609
.	O

Despite	O
reduced	O
treatment	O
margins	I:C0229985
and	O
lack	O
of	O
patient	O
immobilization	O
,	O
stereotactic	O
body	I:C3896609
radiation	I:C3896609
therapy	I:C3896609
with	O
fiducial	O
-	O
based	O
tumor	O
tracking	O
achieves	O
clinically	O
comparable	O
long	O
-	O
term	O
outcomes	O
to	O
other	O
linac	O
-	O
based	O
SBRT	B:C3896609
approaches	I:C3896609
.	O

